Filter zurücksetzen
Stichworte
Arzneimitteltherapie ×
Zeige mehr Stichworte
Inhaltsverzeichnis
  1. 1. Klinische Studie
  2. 2. Routinedokumentation
  3. 3. Register-/Kohortenstudien
  4. 4. Qualitätssicherung
  5. 5. Datenstandard
  6. 6. Patientenfragebogen
  7. 7. Medizinische Fachrichtung
Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

187 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

26672_Common Data Elements Myeloid Leukemia (MDS AML CML) - Global Disease Course

- 20.09.21 - 13 Formulare, 3 Itemgruppen, 11 Datenelemente, 1 Sprache
Itemgruppen: Global Disease Course, Red Cell Transfusion, Platelet Cell Transfusion
Common Data Elements Myeloid Leukemia (MDS, AML, CML) for use in clinical routine and clinical trial documentation. https://www.ncbi.nlm.nih.gov/pubmed/27577388

Physical Examination/Follow up

3 Itemgruppen 14 Datenelemente

Administrative/Demographic Details

1 Itemgruppe 11 Datenelemente

Medical History

3 Itemgruppen 9 Datenelemente

Lab: Cytology/Cytogenetics/Cytochemistry

1 Itemgruppe 29 Datenelemente

Lab: Immunophenotyping

1 Itemgruppe 17 Datenelemente

Lab: Molecular Genetics

1 Itemgruppe 27 Datenelemente

Study SHIP-NEXT_metadata_20240913_NEXT|NEXT0|PHA - x0.pha_quest

- 08.10.24 - 4 Formulare, 1 Itemgruppe, 6 Datenelemente, 2 Sprachen
Itemgruppe: x0.pha_quest
Item catalog SHIP-NEXT part 8

x0.pha_ident

1 Itemgruppe 20 Datenelemente

x0.pha_take

1 Itemgruppe 7 Datenelemente

x0.pha_odm

1 Itemgruppe 5 Datenelemente

Safety, tolerability and pharmacodynamics of Elubrixin in cystic fibrosis patients, NCT00903201 - Sputum collection

- 27.09.21 - 1 Formular, 7 Itemgruppen, 24 Datenelemente, 1 Sprache
Itemgruppen: Administrative data, Dosing date and time, Sputum induction, Sputum sample quality, Sputum sample preparation and hemacytometry, Sample collection summary, Sputum slide results
Study ID: 110399 Clinical Study ID: 110399 Study Title: A randomized, double blind, parallel group, placebo controlled 28 day study to investigate the safety, tolerability and pharmacodynamics of SB-656933 in subjects with cystic fibrosis. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00903201 https://clinicaltrials.gov/ct2/show/NCT00903201?term=NCT00903201 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: SB656933, Placebo Trade Name: N/A Study Indication: Cystic Fibrosis The study consists of a screening, five study visits and a follow-up (time relative to Baseline in days): Visit 1: Screening, Day -28 to -16 Visit 2a: Day -7 to -4 Visit 2b: Day 1 Visit 3: Day 14 Visit 4: Day 21 Visit 5: Day 28 Visit 6: Early Withdrawal/ Follow-up, Day 35 to 42. From day 1 to day 28 the patients will receive daily doses. This document contains the Sputum collection form. It has to be filled in for V2b, V5 and if requiered for logs/ repeats. This document can be filled in as often as necessary for logs/ repeats.

Safety, tolerability and pharmacodynamics of Elubrixin in cystic fibrosis patients, NCT00903201 - Logs and Repeats

- 27.09.21 - 1 Formular, 4 Itemgruppen, 16 Datenelemente, 1 Sprache
Itemgruppen: Administrative Data, Date of visit/assessment, AE/Concomitant medication/Repeat an assessment check question, Liver event
Study ID: 110399 Clinical Study ID: 110399 Study Title: A randomized, double blind, parallel group, placebo controlled 28 day study to investigate the safety, tolerability and pharmacodynamics of SB-656933 in subjects with cystic fibrosis. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00903201 https://clinicaltrials.gov/ct2/show/NCT00903201?term=NCT00903201 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: SB656933, Placebo Trade Name: N/A Study Indication: Cystic Fibrosis The study consists of a screening, five study visits and a follow-up (time relative to Baseline in days): Visit 1: Screening, Day -28 to -16 Visit 2a: Day -7 to -4 Visit 2b: Day 1 Visit 3: Day 14 Visit 4: Day 21 Visit 5: Day 28 Visit 6: Early Withdrawal/ Follow-up, Day 35 to 42. From day 1 to day 28 the patients will receive daily doses. This document contains the Logs and Repeats form.

ATC A - Alimentary Tract and Metabolism

- 20.09.21 - 1 Formular, 1 Itemgruppe, 1 Datenelement, 2 Sprachen
Itemgruppe: Alimentary Tract and Metabolism
modified from epSOS value set 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 http://www.epsos.eu http://www.whocc.no/atc_ddd_index/ WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2015. Oslo, Norway 2014 Copyright ATC index: WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway Copying and distribution for commercial purposes is not allowed. German ATC Codes: Datenquelle des amtlichen ATC-Index mit DDD-Angaben: GKV-Arzneimittelindex im Wissenschaftlichen Institut der AOK (WIdO), AOK Bundesverband GbR Stand September 2015. Nur nicht-kommerzielle Nutzung zulässig

Eligibility HOMe aFers 1 NCT02905539

- 20.09.21 - 1 Formular, 4 Itemgruppen, 36 Datenelemente, 2 Sprachen
Itemgruppen: Inclusion criteria, Exclusion criteria, Result of eligibility criteria verification, Administrative data
Eligibility form Prüfung der Eignung zur Studienteilnahme NCT02905539 A Randomized, Double-blind Comparative Study Comparing Ferric Carboxymaltose (Ferinject) and Iron Isomaltoside 1000 (Monofer) for Iron Substitution in Iron-deficiency Anemia Quelle: Prof. Dr. med. Gunnar Heine Universitätsklinikum des Saarlandes

Multiple sclerosis studies NCT02461069 NCT02419378 - Baseline 1st cycle Trial Medication Multiple Sclerosis ALAIN01 NCT02419378

- 20.09.21 - 18 Formulare, 2 Itemgruppen, 16 Datenelemente, 1 Sprache
Itemgruppen: Medication, Trial Medication RQG
Screening, Baseline and Visit 1 CRFs of DIMAT-MS and ALAIN studies for semantic analysis of Multiple Sclerosis study documentation. Provided by Prof. Dr. Luisa Klotz of the Department of Neurology of the University Hospital Muenster.

Baseline: Repitition of Assessments: MRI Multiple Sclerosis ALAIN01 NCT02419378

1 Itemgruppe 15 Datenelemente

Baseline: MRI Multiple Sclerosis ALAIN01 NCT02419378

1 Itemgruppe 15 Datenelemente

Baseline: CSF Multiple Sclerosis ALAIN01 NCT02419378

1 Itemgruppe 32 Datenelemente

Visit 1 (Screening) Part 2/2, Lab; Medical Examination, DIMAT-MS, Relapsing Remitting Multiple Sclerosis NCT02461069

7 Itemgruppen 40 Datenelemente

Pharmacokinetics

- 20.09.21 - 1 Formular, 1 Itemgruppe, 23 Datenelemente, 1 Sprache
Itemgruppe: Pharmacokinetics
Record detailed information about the collection of biological samples for analysis of the presence and quantity of the study agent and/or its metabolites. Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=AD257392-F827-EFBD-E040-BB89AD434E1E

Medication Form Melanoma (NCT01274338)

- 20.09.21 - 1 Formular, 6 Itemgruppen, 35 Datenelemente, 1 Sprache
Itemgruppen: Header, On Treatment Reporting Period, OFF TREATMENT, Corticosteroid Medication, Immunosuppressant Medication, Hormonal Replacement Therapy Medication
E1609 Corticosteroid/Immunosuppressant/Hormone Replacement Medication Form Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery NCT01274338 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B1F0BB2E-39FF-B3FA-E040-BB89AD430140

ATC 2nd level

- 20.09.21 - 1 Formular, 1 Itemgruppe, 1 Datenelement, 2 Sprachen
Itemgruppe: ATC 2nd level
modified from epSOS value set 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 www.epsos.eu

ATC J - Antiinfectives for systemic use

- 20.09.21 - 1 Formular, 1 Itemgruppe, 1 Datenelement, 2 Sprachen
Itemgruppe: Antiinfectives for systemic use
modified from epSOS value set 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 http://www.epsos.eu http://www.whocc.no/atc_ddd_index/ WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2015. Oslo, Norway 2014 Copyright ATC index: WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway Copying and distribution for commercial purposes is not allowed. German ATC-Index: Datenquelle des amtlichen ATC-Index mit DDD-Angaben: GKV-Arzneimittelindex im Wissenschaftlichen Institut der AOK (WIdO), AOK Bundesverband GbR Stand September 2015. Nur nicht-kommerzielle Nutzung zulässig

ATC R - Respiratory System

- 20.09.21 - 1 Formular, 1 Itemgruppe, 1 Datenelement, 2 Sprachen
Itemgruppe: Respiratory System
modified from epSOS value set 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 http://www.epsos.eu http://www.whocc.no/atc_ddd_index/ WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2015. Oslo, Norway 2014 Copyright ATC index: WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway Copying and distribution for commercial purposes is not allowed. German ATC-Index: Datenquelle des amtlichen ATC-Index mit DDD-Angaben: GKV-Arzneimittelindex im Wissenschaftlichen Institut der AOK (WIdO), AOK Bundesverband GbR Stand September 2015. Nur nicht-kommerzielle Nutzung zulässig

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video